MedTrace Logo

Prevalence of Sleep Disturbances in Bullous Pemphigoid Patients.

NCT07188402 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 122

Last updated 2025-09-23

No results posted yet for this study

Summary

Bullous pemphigoid (BP) is the most common autoimmune blistering disorder. The incidence of BP has increased due to increased life expectancy, particularly in developed countries, which can be associated with multiple geriatric comorbidities and polypharmacy.

Epidemiological studies of BP have shown that the incidence ranges from 2.5 to 42.8 cases/million/year in European countries.

BP affects older adults with multiple comorbidities, primarily neurological diseases such as multiple sclerosis, dementia, Parkinson's disease, epilepsy, and stroke, which are usually diagnosed before BP.

Diagnosis is based on clinical suspicion combined with immunopathological investigations. The clinical chronological course is characterized by relapses and remissions. The goals of PB treatment are to stop the development of new skin lesions, healing of old lesions, and symptomatic therapy.

Conditions

  • Bullous Pemphigoid (BP)

Interventions

OTHER

Prevalence of sleep disturbances in patients with bullous pemphigoid

Use of a questionnaire assessing the Insomnia Severity Index (ISI)

OTHER

Prevalence of sleep disturbances in healthy volunteers without bullous pemphigoid

Use of a questionnaire assessing the Insomnia Severity Index (ISI)

Sponsors & Collaborators

  • University Hospital, Rouen

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-04
Primary Completion
2023-07-10
Completion
2024-01-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07188402 on ClinicalTrials.gov